source
- Novo Nordisk vows to launch five multi-blockbuster drugs by 2030 as it shifts toward consumer-style productsNovo Nordisk used its London capital markets day to reassure investors that the company will broaden its pipeline and market new medicines more like consumer products than traditional drugs. The C…
- New KRAS-targeting drug daraxonrasib approved for pancreatic cancer as experts call for $100 billion NIH budgetThe FDA has approved daraxonrasib, a therapy from Revolution Medicines that targets the KRAS mutation in pancreatic cancer. The drug is intended for patients who have already received treatment and…